Rabnoor Alam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rabnoor Alam has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Pandeya
Graphic Era University, Bellroad, Clement town, Dehradun, Uttarakhand, India
1 shared publication Arshi Aquil
Jamia Hamdard, New Delhi, India
1 shared publication- Kamini Bhardwaj
Department of Pharmacy, Raj Kumar Goel Institute of Technology (Pharmacy), 5-Km. Stone, Delhi-Meerut Road, Ghaziabad, Uttar Pradesh, 201003, India
1 shared publication Mohd Akhtar
Jamia Hamdard, New Delhi, India
1 shared publicationMohd Aqil
Jamia Hamdard, New Delhi, India
1 shared publicationMohd Mujeeb
Jamia Hamdard, New Delhi, India
1 shared publication
Latest Publications
- 5 September 2025
- Published by IGI Global Scientific Publishing
- p. 1-32
Current Treatment Modalities Associated With Glioblastoma and Its Merits and Demerits
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor marked by rapid progression, diffuse infiltration, and poor prognosis. Conventional treatments—surgical resection, radiotherapy, and temozolomide chemotherapy—offer limited success due to intratumoral heterogeneity, the blood-brain barrier (BBB), glioma stem-like cells. Novel immunotherapeutic strategies, including immune checkpoint inhibitors, CAR T and CAR-NK cells, dendritic cell vaccines, and oncolytic virotherapy, are under investigation to improve immune-mediated tumor eradication. Tumor-treating fields (TTFs) and targeted molecular therapies show additional promise. This chapter explores the molecular and metabolic landscape of GBM, reviews current and emerging therapies, and underscores the urgent need for integrated, personalized treatment strategies to improve patient outcomes.
- 5 September 2025
- Published by IGI Global Scientific Publishing
- p. 1-32
Current Treatment Modalities Associated With Glioblastoma and Its Merits and Demerits
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor marked by rapid progression, diffuse infiltration, and poor prognosis. Conventional treatments—surgical resection, radiotherapy, and temozolomide chemotherapy—offer limited success due to intratumoral heterogeneity, the blood-brain barrier (BBB), glioma stem-like cells. Novel immunotherapeutic strategies, including immune checkpoint inhibitors, CAR T and CAR-NK cells, dendritic cell vaccines, and oncolytic virotherapy, are under investigation to improve immune-mediated tumor eradication. Tumor-treating fields (TTFs) and targeted molecular therapies show additional promise. This chapter explores the molecular and metabolic landscape of GBM, reviews current and emerging therapies, and underscores the urgent need for integrated, personalized treatment strategies to improve patient outcomes.
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 18 (1) , 5-14
Artificial Intelligence in Pharmacovigilance and COVID-19
: The history of pharmacovigilance started back 169 years ago with the death of a 15- year-old girl, Hannah greener. However, the Thalidomide incident of 1961 brought a sharp change in the pharmacovigilance process, with adverse drug reaction reporting being systematic, spontaneous, and regulated timely. Therefore, continuous monitoring of marketed drugs was essential to ensure the safety of public health. Any observed adverse drug reaction detected by signals was to be reported by the health profession. Moreover, signal detection became the primary goal of pharmacovigilance based on reported cases. Among various methods used for signal detection, the Spontaneous Reporting System was most widely preferred; although, it had the limitation of "under- reporting”. Gradually, the World Health Organization collaborating centre and “Uppsala Monitoring Centre” were established in 1978 for international monitoring of drugs. The centre was responsible for operating various databases like vigiflow, vigibase, vigilyze, and vigiaccess. Recently, huge data could be generated through spontaneous reporting linked with computational methods, such as Bayesian Framework, E-Synthesis.: Furthermore, drug safety surveillance at an early stage prior to the official alerts or regulatory changes was made possible through social media. In addition, India created a National Pharmacovigilance Program, and Schedule Y of the Drug and Cosmetic Act 1945 was reviewed and amended in 2005. The collaboration of Information Technology and Pharmaceutical Company can further enhance the awareness regarding artificial intelligence in pharmacovigilance, which was in its infancy until 2017. Artificial intelligence helps improve the quality and accuracy of information much quickly.
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 18 (1) , 5-14
Artificial Intelligence in Pharmacovigilance and COVID-19
: The history of pharmacovigilance started back 169 years ago with the death of a 15- year-old girl, Hannah greener. However, the Thalidomide incident of 1961 brought a sharp change in the pharmacovigilance process, with adverse drug reaction reporting being systematic, spontaneous, and regulated timely. Therefore, continuous monitoring of marketed drugs was essential to ensure the safety of public health. Any observed adverse drug reaction detected by signals was to be reported by the health profession. Moreover, signal detection became the primary goal of pharmacovigilance based on reported cases. Among various methods used for signal detection, the Spontaneous Reporting System was most widely preferred; although, it had the limitation of "under- reporting”. Gradually, the World Health Organization collaborating centre and “Uppsala Monitoring Centre” were established in 1978 for international monitoring of drugs. The centre was responsible for operating various databases like vigiflow, vigibase, vigilyze, and vigiaccess. Recently, huge data could be generated through spontaneous reporting linked with computational methods, such as Bayesian Framework, E-Synthesis.: Furthermore, drug safety surveillance at an early stage prior to the official alerts or regulatory changes was made possible through social media. In addition, India created a National Pharmacovigilance Program, and Schedule Y of the Drug and Cosmetic Act 1945 was reviewed and amended in 2005. The collaboration of Information Technology and Pharmaceutical Company can further enhance the awareness regarding artificial intelligence in pharmacovigilance, which was in its infancy until 2017. Artificial intelligence helps improve the quality and accuracy of information much quickly.